Navigation Links
Vantia Therapeutics' Pipeline Continues to Mature
Date:3/24/2009

SOUTHAMPTON, England, March 24 /PRNewswire/ --

- VA106483 Completes Phase IIa Trial and VA111913 Completes Phase I Dosing

Vantia Therapeutics, a company focusing on first-in-class therapies for unmet medical needs, announces further clinical trial progress with its two lead development compounds, VA106483 for nocturia associated with benign prostatic hypertrophy (BPH) and VA111913 for dysmenorrhoea. The Phase IIa trial of VA106483 has completed, while dosing is complete in the Phase I trial of VA111913. With this news and developments in Vantia's preclinical pipeline, the company is continuing to generate value from its extensive library of small molecule antagonists of hormones and proteases.

Following the completion of the 27-patient Phase IIa trial of VA106483, a vasopressin agonist, results are expected in H1 2009, with the Phase IIb study expected to start in the second half of the year. Up to 200 males with nocturia are expected to be involved in this dose-finding placebo-controlled study, which is expected to complete in the first half of 2010.

Given Vantia Therapeutics' strategy of developing products to the end of proof of concept/Phase IIb trials, the product is expected to be outlicensed for further development after the Phase IIb results. Nocturia in BPH is believed to represent a potential market in excess of $1bn, and VA106483's potential in follow-on indications such as overactive bladder and general nocturia could add significant extra value.

The Phase I trial for VA111913 has recruited the last of its 99 volunteers, and is also expected to report data in H1 2009. Phase IIa trials are expected to start in the second half of this year, involving over 100 patients and completing in H2 2010. VA111913 is a vasopressin antagonist, with dysmenorrhoea (painful menstruation) believed to represent a multibillion dollar market for which there is currently no t
'/>"/>

SOURCE Vantia Therapeutics
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
2. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
3. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
4. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
5. CV Therapeutics Announces Eight Abstracts Accepted for Presentation at the European Society of Cardiology Congress 2007
6. Pharmacopeia Assists the World Health Organization in the Discovery of Novel Therapeutics for the Treatment of Malaria
7. Protalix BioTherapeutics Treats First Patient in Phase III Clinical Trial of prGCD
8. TorreyPines Therapeutics Initiates a Phase I Multiple Dose Clinical Trial of Tezampanel
9. TorreyPines Therapeutics Completes Phase I Multiple Dose Clinical Trial of NGX267, a Selective M1 Agonist for the Potential Treatment of Cognitive Impairment Associated with Schizophrenia
10. Cell Therapeutics, Inc. (CTI) Launches Phase III Study for Pixantrone in Relapsed Indolent Non-Hodgkins Lymphoma (NHL)
11. Cell Therapeutics, Inc. (CTI) Sponsors Panel Discussion on Women and Lung Cancer on Capitol Hill
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2015)... CRY ), a leading medical device and tissue ... today its results for the second quarter and first ... Chairman, President and Chief Executive Officer, said, "During the ... with solid progress on several of our top organizational ... a direct sales model in France, advancing our strategic ...
(Date:7/28/2015)... Minn. , July 28, 2015 ANI ... the Company plans to release its second quarter and ... before the opening of the U.S. financial markets. The ... Relations section of the Company,s website, www.anipharmaceuticals.com . ... Chief Executive Officer, and Charlotte C. Arnold , ...
(Date:7/28/2015)... Oncology, Inc. (OTC: CSBR), engaged in the development of ... and use of oncology drugs, today announced its financial ... Fourth Quarter and Recent Business Highlights: , ... period result , Procured a quarterly record high ... Champions Oncology CEO, stated, "The end of fiscal 2015 ...
Breaking Medicine Technology:CryoLife Reports Second Quarter Financial Results 2CryoLife Reports Second Quarter Financial Results 3CryoLife Reports Second Quarter Financial Results 4CryoLife Reports Second Quarter Financial Results 5CryoLife Reports Second Quarter Financial Results 6CryoLife Reports Second Quarter Financial Results 7CryoLife Reports Second Quarter Financial Results 8CryoLife Reports Second Quarter Financial Results 9CryoLife Reports Second Quarter Financial Results 10CryoLife Reports Second Quarter Financial Results 11CryoLife Reports Second Quarter Financial Results 12CryoLife Reports Second Quarter Financial Results 13CryoLife Reports Second Quarter Financial Results 14ANI Pharmaceuticals Schedules Conference Call for Second Quarter and Year-to-Date 2015 Financial Results 2Champions Oncology Reports Results for Quarter and Full Year Ended April 30, 2015 2Champions Oncology Reports Results for Quarter and Full Year Ended April 30, 2015 3Champions Oncology Reports Results for Quarter and Full Year Ended April 30, 2015 4Champions Oncology Reports Results for Quarter and Full Year Ended April 30, 2015 5Champions Oncology Reports Results for Quarter and Full Year Ended April 30, 2015 6Champions Oncology Reports Results for Quarter and Full Year Ended April 30, 2015 7Champions Oncology Reports Results for Quarter and Full Year Ended April 30, 2015 8Champions Oncology Reports Results for Quarter and Full Year Ended April 30, 2015 9Champions Oncology Reports Results for Quarter and Full Year Ended April 30, 2015 10Champions Oncology Reports Results for Quarter and Full Year Ended April 30, 2015 11
(Date:7/28/2015)... (PRWEB) , ... July 28, 2015 , ... According to ... able to stop the cycle of addiction in lab mice. The study involving isradipine ... for the new prospect of helping their clients overcome drug and alcohol addictions. The ...
(Date:7/28/2015)... ... July 28, 2015 , ... Bipolar disorder is often associated with mood swings ... times a year. The World Health Organization (WHO) has reported that bipolar disorder affects ... Health reveals that the United States has the highest lifetime rate of bipolar disorder ...
(Date:7/28/2015)... ... July 28, 2015 , ... Safeguard ... authorized the Company, from time to time and depending on market conditions, to ... to $25 million. Repurchases will be made in open market or privately negotiated ...
(Date:7/28/2015)... ... 28, 2015 , ... Fertility specialist Dr. Lisa Hasty of Atlanta ... Atlanta Magazine. In Atlanta Magazine's annual Top Doctors issue, Dr. Hasty has been recognized ... peers in the metro area as one of the most respected doctors in Reproductive ...
(Date:7/28/2015)... , ... July 28, 2015 , ... ... Coronary Syndromes (ACS-Heart Attack, Sudden Death, or Angina), many of whom are missed ... the identification of individuals with active yet undetected sub-clinical disease, who are at ...
Breaking Medicine News(10 mins):Health News:Blood Pressure Medication May be the Key to Treating Addiction 2Health News:Blood Pressure Medication May be the Key to Treating Addiction 3Health News:"I Am Not I" Music Video Raises Bipolar Disorder Awareness 2Health News:Safeguard Scientifics Board of Directors Authorizes up to $25 Million Share Repurchase Program 2Health News:Safeguard Scientifics Board of Directors Authorizes up to $25 Million Share Repurchase Program 3Health News:Atlanta Fertility Specialist Named Top Doctor in Atlanta Magazine 2Health News:Atlanta Fertility Specialist Named Top Doctor in Atlanta Magazine 3Health News:Utility of a novel coronary artery disease biomarker algorithm in modifying physician adherence to guideline therapy presented at 20th World Congress on Heart Disease 2
... (HealthDay News) -- In men who,ve had their prostate surgically ... a rise in blood levels of prostate specific antigen (PSA) ... So finds a new study slated to be presented Monday ... in Washington, D.C. The study included 321 smokers ...
... --,More than half of those who develop Alzheimer,s disease before ... signs of the disease are symptoms other than memory problems, ... of 40 people from Barcelona who were found to have ... the age at which the symptoms began, as well as ...
... of workshops held by the Institute of Medicine explored ... to harness the full potential of new digital technologies ... efficiency and apply knowledge to real-time care decisions. , ... for Continuous Improvement in Health and Health Care recaps ...
... strong commitment to medical and health research and recognize ... and the nation,s economy, according to a new statewide ... Ohio Medical University (NEOMED). A strong majority ... important42% say very importantto the state,s economy. Eight in ...
... is the fourth-most-common cancer in men and one of ... death. After initial diagnosis and surgery, patients must return ... time-consuming and uncomfortable bladder scan. Tumors recur in more ... Washington are proposing a more automated approach that could ...
... Researchers at Sandia National Laboratories have developed a ... about exactly how and why a cell,s defenses ... successfully fending off others like E.coli. The approach ... which could open doors to new diagnostic, prevention ...
Cached Medicine News:Health News:Research Shows Early Onset Alzheimer's Disease Sometimes Missed 2Health News:Ohio residents: Medical and health research important to state's economy, jobs and incomes 2Health News:Ohio residents: Medical and health research important to state's economy, jobs and incomes 3Health News:Digital imaging software to create a 'Google Earth' view of the bladder 2Health News:Digital imaging software to create a 'Google Earth' view of the bladder 3Health News:Sandia Labs unlocks secrets of plague with stunning new imaging techniques 2Health News:Sandia Labs unlocks secrets of plague with stunning new imaging techniques 3
Exclusive oxidized regenerated cellulose technology. The only oxidized regenerated cellulose hemostat line, surgicel absorbable hemostat delivers a unique combination of effectiveness, absorbability,...
The Codman steerable neuroendoscope combines a high quality fiberoptic image with the flexibility and steerability required for many neuroendoscopic applications....
... Optimum visualization of the spine. ... room are provided for all ... the arms in both superior ... spine can be positioned for ...
Adjust-A-Tip cautery....
Medicine Products: